Phase II Trial Of Smo/ Akt/ Nf2/Cdk Inhibitors In Progressive Meningiomas With Smo/ Akt/ Nf2/Cdk Pathway Mutations
Posted Date: May 15, 2019
- Investigator: Rekha Chaudhary
- Specialties: Cancer, Oncology
- Type of Study: Drug
This phase II trial will study how well vismodegib, focal adhesion kinase (FAK) inhibitor GSK2256098, and capivasertib work in treating patients with meningioma that is growing, spreading, or getting worse (progressive). Vismodegib, FAK inhibitor GSK2256098, capivasertib, and abemaciclib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Efficacy will be determined by progression free survival and response rate defined as a confirmed complete response or partial response. There will be 4 arms in this study. In arm A, patients will receive vismodegib PO QD. In arm B, Patients will receive FAK inhibitor GSK2256098 PO BID. In arm 3, Patients will receive capivasertib PO BID on days 1-4. In arm 4, Patients will receive abemaciclib PO Q12H.
Criteria:
Patients Must Have Histologically Proven Intracranial Meningioma As Documented By Central Pathology Review. Presence Of Smo, Ptch1, Nf2, Cdkn2a, Akt1, Pik3ca, Pten Mutations, Cdkn2a Copy Number Loss, Cdk4, Cdk6, Ccnd1, Ccnd2, Ccnd3, Or Ccne1 Copy Number G
Keywords:
A071401, Cancer, Brain, Smo/Akt/Nf2 Mutation, Meningioma
For More Information:
Uc Cancer Center
513-584-7698
cancer@uchealth.com